脂质体紫杉醇与奈达铂联合治疗老年非小细胞肺癌的临床疗效  

Clinical efficacy of lipsomal paclitaxel plus nedaplatin in treatment of advanced non-small cell lung cancer

作　　者：王琦[1] 贠利新[2] 徐玉清[3] 

机构地区：[1]广西钦州市第一人民医院肿瘤内科,广西钦州535099 [2]广西钦州市第一人民医院心血管外科,广西钦州535099 [3]哈尔滨医科大学附属第二医院肿瘤内科,黑龙江哈尔滨150081

出　　处：《哈尔滨医科大学学报》2016年第6期565-568,共4页Journal of Harbin Medical University

摘　　要：目的观察脂质体紫杉醇与奈达铂联合治疗老年非小细胞肺癌的临床疗效。方法选取2014年7月~2015年9月于广西钦州市第一人民医院肿瘤科住院接受治疗的老年非小细胞肺癌Ⅲ~Ⅳ期患者60例,采用TP化疗方案(脂质体紫杉醇175 mg/m^2,奈达铂80~100 mg/m^2静脉滴注),3周为1个疗程,化疗不少于2个周期。用药2个周期后,对药物的疗效进行评估。结果患者的生存期得以改善,用药产生的毒副作用轻,有效率为33.3%。生活质量得到提高,血清中的CEA也相应下降。结论脂质体紫杉醇与奈达铂联合治疗老年非小细胞肺癌的临床效果显著。Objective To observe the efficacy of combination therapy of liposome-paclitaxel and nedaplat for advanced non-small cell lung cancer（NSCLC）. Methods From July 2014 to September 2015, totally 60 NSCLC patients were collected. TP chemotherapy regimen was adopted by intravenous injection with liposome-paelitaxel at a dosage of 175 mg/m2 and nedaplat at a dosage of 80 - 100 mg/m2. Three weeks were a cycle of treatment and at least two cycles of chemotherapy was processed. After two treatment cycles, the efficacy was assessed. Results The survival time of the patients was prolonged, and the side effect was reduced. The total effective rate was 33.3%. The patients quality of life was improved. The serum CEA was also correspondingly declined. Conclusion The combination therapy of liposome-paclitaxel plus nedaplatin is remarkably effective in the treatment of advanced non-small cell lung cancer in clinic.

关 键 词：脂质体杉醇 奈达铂 老年非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]